Doxorubicin Hydrochloride Injectable, Liposomal
NDC Package 70710-1530-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Doxorubicin Hydrochloride injectables is doxorubicin hydrochloride liposome injection is contraindicated in patients who have a history of severe hypersensitivity reactions, including anaphylaxis, to doxorubicin hydrochloride [see Warnings and Precautions (5.2)]. This formulation utilizes a injectable, liposomal delivery system. Marketed by Zydus Pharmaceuticals Usa Inc., this product is identified by NDC 70710-1530 and is authorized under FDA application ANDA212299.

Identification & Billing

NDC Package Code
70710-1530-1
Package Description
1 VIAL, SINGLE-DOSE in 1 CARTON / 10 mL in 1 VIAL, SINGLE-DOSE
Product Code
70710-1530
11-Digit Billing Format
70710153001
RxNorm Crosswalk
  • RxCUI: 1790115 - DOXOrubicin HCl liposome 20 MG in 10 ML Injection
  • RxCUI: 1790115 - 10 ML doxorubicin hydrochloride liposome 2 MG/ML Injection
  • RxCUI: 1790115 - doxorubicin hydrochloride liposome 20 MG per 10 ML Injection
  • RxCUI: 1790127 - DOXOrubicin HCl liposome 50 MG in 25 ML Injection
  • RxCUI: 1790127 - 25 ML doxorubicin hydrochloride liposome 2 MG/ML Injection

Clinical Specifications

Proprietary Name
Doxorubicin Hydrochloride
Non-Proprietary Name
Doxorubicin Hydrochloride
Substance Name
Doxorubicin Hydrochloride
Dosage Form
Injectable, Liposomal - An injection, which either consists of or forms liposomes (a lipid bilayer vesicle usually composed of phospholipids which is used to encapsulate an active drug substance).
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
DOXORUBICIN HYDROCHLORIDE 2 mg/mL
Pharmacologic Class
Usage Information
Doxorubicin hydrochloride liposome injection is contraindicated in patients who have a history of severe hypersensitivity reactions, including anaphylaxis, to doxorubicin hydrochloride [see Warnings and Precautions (5.2)].

Regulatory & Marketing

Labeler Name
Zydus Pharmaceuticals Usa Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA212299
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
09-14-2020
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

Q2050
Source: ASP
Doxorubicin inj 10mg
HCPCS Dosage 10 MG
Units / Pkg 2

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70710-1530-1 identifies a specific commercial package of 1 vial, single-dose in 1 carton / 10 ml in 1 vial, single-dose of Doxorubicin Hydrochloride, a human prescription drug labeled by Zydus Pharmaceuticals Usa Inc.. This injectable, liposomal is formulated for intravenous use and contains doxorubicin hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Zydus Pharmaceuticals Usa Inc. on September 14, 2020. The current certification is valid through December 31, 2027.

How is this Zydus Pharmaceuticals Usa Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70710153001. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
70710-1530-1
11-Digit CMS (5-4-2)
70710-1530-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.